SCHEDULE: Alyeska Investment Group Discloses 5.6% Stake in Achieve Life Sciences
Beneficial Ownership Disclosure
Alyeska Investment Group, L.P. and its affiliates reported a 5.6% beneficial ownership stake in Achieve Life Sciences, Inc., primarily through common stock and warrants.
Summary
- Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 2,982,722 shares of Achieve Life Sciences, Inc. common stock.
- This ownership represents 5.6% of the company's outstanding common stock.
- The reported stake comprises 178,389 shares of common stock and warrants to purchase an additional 2,804,333 shares.
- The reporting persons hold shared voting and shared dispositive power over all 2,982,722 beneficially owned shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing indicates a significant institutional investor, Alyeska Investment Group, holds a 5.6% stake in Achieve Life Sciences, Inc., which includes common stock and warrants. This continued substantial ownership by a professional investment group can be viewed as a mild positive signal, suggesting ongoing interest in the company's prospects.
Positives
- A significant institutional investor, Alyeska Investment Group, maintains a substantial stake (5.6%) in Achieve Life Sciences, Inc., indicating continued interest.
- The investment is stated to be in the ordinary course of business, not for control-influencing purposes, suggesting a passive investment strategy.
Risks
- The filing itself does not detail company-specific risks for Achieve Life Sciences, Inc., as it primarily serves as a disclosure of ownership position.
Industry Context
This filing reflects an institutional investor's continued or adjusted stake in a publicly traded biotechnology or pharmaceutical company, which is a common practice for investment funds managing diversified portfolios.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder may instill confidence or provide insight into institutional interest in the company.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event requiring the filing of this statement |
| 11/06/2025 | Date of Issuer's Prospectus filing used for outstanding share count calculation |
| 11/14/2025 | Date of filing of this Schedule 13G Amendment No. 1 |
Keywords
Achieve Life Sciences, Alyeska Investment Group, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.